Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.